Tulrampator
Based on 2 publication(s) in Google Scholar
Tulrampator (S-47445) is an orally active selective AMPA receptor modulator. Tulrampator possesses procognitive, enhancing synaptic plasticity, anti-depressant-anxiolytic-like, procognitive and potential neuroprotective properties. Tulrampator can be used for research of alzheimer’s disease and in major depressive disorder.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.39%
- CAS No.: 1038984-31-4
- Formule: C20H17FN4O3
- Masse moléculaire:380.37
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Neuronal Signaling Compound Library
HY-L013
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
Clinical Compound Library
HY-L026
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neuroprotective Compound Library
HY-L070
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Angiogenesis-Related Compound Library
HY-L088
-
Glucose Metabolism Compound Library
HY-L092
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Activators Library
HY-L159
-
Ion Channel Compound Library
HY-L166
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Tulrampator
MoreVoir tous les produits spécifiques à Isoform iGluR
More
Activité biologique
AMPAR[1]
Tulrampator (0.1 μM, 2 days) markedly enhances the amplitude of the glutamate-evoked current and prolongs the response in HEK-293 cells[1].
Tulrampator (0.1-10 μM, 24 h) shows absence of toxicity on rat primary cortical cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:rat primary cortical cells
-
Concentration:0.1 μM, 3 μM, 10 μM
-
Incubation Time:24 h
-
Result:Did not potentiate glutamatemediated toxicity on rat primary cortical neuronal culture,at 0.03-100 μM glutamate.
Tulrampator (1-10 mg/kg, Intraperitoneal injection, once a day for 4 weeks) reverts olfactory bulbectomy (OB)-induced hyperactivity and anxiety in bilateral olfactory bulbectomy mice model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:chronic corticosterone administration (CORT) mice[2]
-
Dosage:0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg
-
Administration:Oral gavage (p.o.)
-
Result:Reversed anxio-depressive phenotype in a neurogenesis-dependent task.
Decreased the corticosterone-induced increase in emotionality.
Had a rapid onset of effect on anhedonia in the rat Chronic Mild Stress (CMS) model.
Stimulated cell proliferation, survival and neuronal maturation in the dentate gyrusof the hippocampus.
-
Animal Model:bilateral olfactory bulbectomy mice model[3]
-
Dosage:1 mg/kg, 3 mg/kg, 10 mg/kg
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Significantly reverted OB-induced hyperactivity after 28 days.
Increased open field central activity in OB mice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1038984-31-4
-
Appearance Solid
-
Masse moléculaire 380.37
-
Formule C20H17FN4O3
-
Color Light yellow to yellow
-
SMILES
O=C(N(C1CC1)CO2)C3=C2C=C4C(N=NN(CCC5=CC(F)=CC=C5)C4=O)=C3
-
Synonyms
CX-1632; S-47445
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
NPJ Parkinsons Dis
Oligomeric alpha-synuclein causes early synaptic dysfunction of the corticostriatal pathway associated with non-motor symptoms. [Abstract]2025 Jul 29;11(1):220. PMID: 40730592 -
Brain Behav Immun
Anti-GluA3 autoantibodies define a new sub-population of frontotemporal lobar degeneration patients with distinct neuropathological features. [Abstract]2024 May:118:380-397. PMID: 38485064
Solvant et solubilité
DMSO : 20 mg/mL (52.58 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.17 mg/mL (5.70 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.17 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6290 mL | 13.1451 mL | 26.2902 mL | 65.7255 mL |
| 5 mM | 0.5258 mL | 2.6290 mL | 5.2580 mL | 13.1451 mL | |
| 10 mM | 0.2629 mL | 1.3145 mL | 2.6290 mL | 6.5725 mL | |
| 15 mM | 0.1753 mL | 0.8763 mL | 1.7527 mL | 4.3817 mL | |
| 20 mM | 0.1315 mL | 0.6573 mL | 1.3145 mL | 3.2863 mL | |
| 25 mM | 0.1052 mL | 0.5258 mL | 1.0516 mL | 2.6290 mL | |
| 30 mM | 0.0876 mL | 0.4382 mL | 0.8763 mL | 2.1908 mL | |
| 40 mM | 0.0657 mL | 0.3286 mL | 0.6573 mL | 1.6431 mL | |
| 50 mM | 0.0526 mL | 0.2629 mL | 0.5258 mL | 1.3145 mL |
Tulrampator Related Classifications
HY-109046 Related Classifications
Powered by Bioz